Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vorolanib - Betta Pharmaceuticals/Tyrogenex

Next Previous
X
Search
Drug Profile

Vorolanib - Betta Pharmaceuticals/Tyrogenex

Alternative Names: [14C]CM082; Challenge Meditech 082; CM-082; Fumena; X-82

Latest Information Update: 19 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tyrogenex
  • Developer Betta Pharmaceuticals Co Ltd; Renmin Hospital of Wuhan University; Tyrogenex; Washington University School of Medicine; Xcovery Holdings
  • Class Amides; Antineoplastics; Eye disorder therapies; Fluorinated hydrocarbons; Indoles; Pyrroles; Pyrrolidines; Small molecules
  • Mechanism of Action Platelet-derived growth factor beta receptor antagonists; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Renal cell carcinoma
  • Phase II Age-related macular degeneration; Malignant melanoma; Non-small cell lung cancer; Small cell lung cancer; Solid tumours; Wet age-related macular degeneration
  • Phase I/II Malignant thymoma; Pancreatic cancer
  • No development reported Choroidal neovascularisation; Gastric cancer

Most Recent Events

  • 16 Aug 2024 Launched for Renal cell carcinoma (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO) (Betta Pharmaceuticals pipeline, August 2024)
  • 28 Jul 2023 No recent reports of development identified for phase-I development in Choroidal-neovascularisation(In adults) in China (PO, Tablet)
  • 28 Jul 2023 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO, Tablet)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top